孤立性快速眼动睡眠行为障碍与帕金森病患者尿α-突触核蛋白聚集体水平升高
本研究采用表面荧光强度分布分析(sFIDA)检测尿液中α-突触核蛋白聚集体,发现帕金森病(PD)患者及作为PD前驱期的孤立性快速眼动睡眠行为障碍患者尿聚集体浓度均高于健康对照;PD对对照的敏感度和特异度分别为83%和65%,孤立性快速眼动睡眠行为障碍对对照分别为89%和62%。
要点
- 尿α-突触核蛋白聚集体在PD及孤立性快速眼动睡眠行为障碍患者中较健康对照升高。
- sFIDA检测尿聚集体对PD的敏感度83%、特异度65%。
- sFIDA检测对孤立性快速眼动睡眠行为障碍的敏感度89%、特异度62%。
核心结论
- PD及孤立性快速眼动睡眠行为障碍患者尿α-突触核蛋白聚集体浓度高于健康对照,sFIDA在诊断突触核蛋白病方面具有潜力。
研究设计与样本
- 研究采用表面荧光强度分布分析(sFIDA)测量尿液中的α-突触核蛋白聚集体,比较PD患者、孤立性快速眼动睡眠行为障碍患者与健康对照。
主要发现
- PD患者及孤立性快速眼动睡眠行为障碍患者尿α-突触核蛋白聚集体浓度均高于健康对照。
- PD对对照的敏感度为83%、特异度为65%;孤立性快速眼动睡眠行为障碍对对照的敏感度为89%、特异度为62%。
关键数值与推荐
- PD对健康对照:敏感度83%,特异度65%。
- 孤立性快速眼动睡眠行为障碍对健康对照:敏感度89%,特异度62%。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson's disease (PD) is a neurodegenerative disorder characterized by α-synuclein aggregation in neurons. Recent advances suggest α-synuclein aggregates could serve as a biomarker for PD and related synucleinopathies. This study used surface-based fluorescence intensity distribution analysis (sFIDA) to measure α-synuclein aggregates in urine. Patients with PD and isolated rapid eye movement sleep behavior disorder, a precursor to PD, had elevated concentrations compared with healthy controls. Sensitivity and specificity were 83% and 65% for PD versus controls and 89% and 62% for isolated rapid eye movement sleep behavior disorder versus controls. The findings highlight sFIDA's potential for diagnosing synucleinopathies. ANN NEUROL 2025;98:147-151.
引用
- Müller L, Özdüzenciler P, Schedlich-Teufer C, et al. Elevated α-Synuclein Aggregate Levels in the Urine of Patients with Isolated REM Sleep Behavior Disorder and Parkinson's Disease. Ann Neurol. 2025. PMID: 40285625. doi:10.1002/ana.27250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。